
Results prove that the company's blood test can help identify which patients are likely to have a relapse within 24-60 months.
Glycominds Ltd. reported that it had reached an important milestone in developing personalized therapy approaches for patients with multiple sclerosis. The company said that it has discovered a method for predicting clinical episodes in people who suffer from multiple sclerosis. These test results have proven with statistical significance that the gMS®Pro CDMS blood test has a good chance of identifying which patients are likely to have a relapse within 24-60 months.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1092